# Teneobio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/teneobio

- Industry: Biotechnology
- Headquarters: Newark, US
- Website: www.teneobio.com
- Total disclosed funding: $34M
- Latest round: Series A (Dec 31, 2016)
- Investors on record: 2

## About

Based in California, US, Teneobio, Inc. operates as a biotechnology company that engages in the development of biologics for the treatments of cancer, autoimmunity, and infectious diseases. In October 2021, Amgen Inc. acquired Teneobio, Inc. from Lightspeed Venture Partners and Sutter Hill Ventures, for USD 800 million, with potential additional payments totaling up to USD 1.6 billion.

Teneobio specializes in the development of bispecific and multispecific, heavy-chain antibody technologies to redirect the immune system to fight disease. Its notable contributions include advanced T cell engagers and proprietary antibody platforms. The company’s key asset was TNB-585, a Phase 1 bispecific T cell engager aimed at treating metastatic castrate-resistant prostate cancer, alongside several promising preclinical oncology assets.

## Funding rounds

- Series A, Dec 31, 2016, $34M — Lightspeed Venture Partners, Sutter Hill Ventures

## Investors

- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series A
- Sutter Hill Ventures (https://capitalatlas.ai/funds/sutter-hill-ventures) — Series A